Fig. 3

8R70CARs enhance T-cell trafficking and antitumor efficacy. a The treatment plan in the GBM model. i720 transduced U87 tumor cells (5 × 10⁴/mouse) were implanted i.c. on day 0, followed by fractionated local IR on day 10 and 11 (4.5 Gy/day) and i.v. administration of the CARs or vector T cells on day 17. IVIS images for luminescence (T cells) and fluorescence (tumors) were taken. b, c T-cell migration and tumor growth at a region of interest (ROI, highlighted with yellow circles) 1, 2, and 6 days after the CAR T-cell treatment. d, e Quantification of T-cell migration to the ROI, 2 days after the T-cell transfer from (b) and tumor growth, 6 days after the T-cell transfer from (c). f Survivals (n = 4–5/group) from (b) and (c). g The treatment plan in an ovarian cancer model. i720 transduced SK-OV-3 tumor cells (1 × 10⁶/mouse) were implanted s.c. on day 0, followed by fractionated local IR on day 10 and 11 (4.5 Gy/day) and the T cells i.v. on day 18. h CAR T cells  (upper panel) and tumor size (lower panels) in the ROI, after the CAR T-cell transfer. i CAR T-cell migration to ROI 3 days after the transfer (h, upper panel). j Tumor size 10 days after the transfer (from  h, lower panel). k Survivals (n = 5–9/group) from (h). l The treatment plan in a pancreatic cancer model. i720 transduced PANC-1 tumor cells (1 × 10⁶/mouse) were implanted s.c. on day 0, followed by fractionated local IR on day 6 and 8 (4.5 Gy/day) and i.v. injection of the T cells on day 13. m Imaging of the CAR T cells in ROI (upper panel, 3 days post T-cell transfer) and tumor size (lower panels) after the CAR T-cell transfer. n CAR T-cell migration in ROI, 3 days after the transfer. o, p Tumor volumes and survivals after the CAR treatment. The boxplots represent the mean and minimum-to-maximum range. The Mann–Whitney U test for (d, e, i, j, n), two-way ANOVA for (o), and the log-rank test for (f, k, p). *p < 0.05, **p < 0.01, ***p < 0.001